Key Points
- Insider sale: Teresa Brophy Bair sold 31,487 Kura Oncology shares for approximately $397,681, reducing her position by 13.88% to 195,444 shares.
- Quarterly results: Kura reported a quarterly loss of $0.77 per share, beating analysts’ estimate of a $0.88 loss, while revenue of $20.87 million exceeded expectations.
- Analyst outlook: The stock has a “Moderate Buy” consensus rating, with a $25.62 average price target versus its recent share price near $11.89, although one firm maintains a sell rating.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Teresa Brophy Bair sold 31,487 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the completion of the sale, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Kura Oncology Price Performance
Shares of NASDAQ:KURA opened at $11.89 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The business's fifty day moving average price is $10.53 and its two-hundred day moving average price is $9.46. The stock has a market cap of $1.06 billion, a PE ratio of -3.53 and a beta of 0.38. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $12.90.
Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to analysts' expectations of $20.16 million. On average, analysts forecast that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.
Institutional Trading of Kura Oncology
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Kura Oncology during the 2nd quarter valued at about $115,286,000. State Street Corp boosted its position in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company's stock worth $51,234,000 after acquiring an additional 1,587,959 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Kura Oncology in the second quarter worth approximately $12,735,000. Jacobs Levy Equity Management Inc. grew its holdings in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company's stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Kura Oncology in the second quarter valued at approximately $10,927,000.
Analysts Set New Price Targets
A number of research firms have issued reports on KURA. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a report on Thursday, June 4th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kura Oncology in a research note on Friday, July 17th. Oppenheimer set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and a consensus price target of $25.62.
Read Our Latest Stock Analysis on Kura Oncology
Kura Oncology Company Profile
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
